Psychiatrist Kristina Deligiannidis MD in professional attire

Kristina M. Deligiannidis, MD

Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States

  • 10Articles
  • 102.6KReads
  • 2010–2026Active
  • 44Collaborators
  • 245Citations

About

Kristina M. Deligiannidis, MD, affiliated with the Feinstein Institutes for Medical Research at Northwell Health in Manhasset, New York, has published extensively on psychiatric conditions affecting women, including major depressive disorder, postpartum depression, and premenstrual dysphoric disorder. Her work encompasses clinical trials and reviews related to neuroactive steroids, antidepressant augmentation, and management of psychosis in the peripartum period. She has also contributed to research on schizophrenia and schizoaffective disorders, with a focus on gender-specific treatment considerations and therapeutic drug monitoring during pregnancy and postpartum.

Publications

What's Next for PPD Treatment | Inhaled Mebufotenin (GH001) Phase 2a Results
Webinar

What's Next for PPD Treatment | Inhaled Mebufotenin (GH001) Phase 2a Results

July 29, 2026

Kristina Deligiannidis, MD, presents phase 2a results for inhaled GH001 (mebufotenin), a psychedelic-based therapeutic that produced same-day remission of postpartum depression in an open-label trial, with rapid clearance from...
JCP
Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression
Original Research

Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression

June 3, 2026

Mebufotenin (GH001) demonstrated rapid and significant improvements in depressive symptoms and remission of postpartum depression.
, , , et al
JCP
Evolving Research on Postpartum Depression Pathophysiology and Treatment
Educational Activity

Evolving Research on Postpartum Depression Pathophysiology and Treatment

August 14, 2023

Research on neuroactive steroids reveals their role in perinatal depression, leading to development of novel therapeutics. These emerging treatments hold promise for faster onset and lasting effects.  
,
JCP
The GABA Pathway and New Clinical Trial Data in MDD and PPD
Supplement Article

The GABA Pathway and New Clinical Trial Data in MDD and PPD

March 16, 2023

Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.
,
JCP
Effect of Zuranolone on Anxiety and Insomnia in Postpartum Depression
Original Research

Effect of Zuranolone on Anxiety and Insomnia in Postpartum Depression

January 30, 2023

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived functional health in patients with PPD.
, , , et al
JCP
ASCP Corner

Long-Acting Injectable Antipsychotic Use During Pregnancy

November 24, 2020

Women with psychotic and mood disorders are at greater risk of symptoms during pregnancy, but some clinicians avoid use of LAIs in these patients due to safety concerns. This...
, , , et al
JCP
ASCP Corner

Premenstrual Dysphoric Disorder Treatment

February 4, 2020

Read an article summarizing the treatment options for Premenstrual Dysphoric Disorder (PMDD).
,
JCP
ASCP Corner

Postpartum Psychosis Treatment

November 7, 2017

Read an article summarizing the diagnosis of postpartum psychosis as well as treatment and prevention strategies.
, ,
JCP
Original Research

Antidepressant Augmentation Using the N-Methyl-d-Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial

October 15, 2013

, , , et al
JCP
Article

A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (STOP-PD): Gender and Age as Predictors of Response and Treatment-Associated Changes in Body Mass Index and Metabolic Measures

October 15, 2013

, , , et al
JCP
ASCP Corner

Therapeutic Drug Monitoring in Pregnant and Postpartum Women: Recommendations for SSRIs, Lamotrigine, and Lithium

May 15, 2010

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe